Pfizer Inc. (PFE) saw its value increase by 0.45% as the stock gained $0.14 to finish the day at a closing price of $31.42. The stock was lighter in trading and has fluctuated between $28.25-$37.39 per share for the past year. The shares, which traded within a range of $31.26 to $31.54 during the day, are down by -2.06% in the past three months and down by -12.74% over the past six months. It is currently trading -3.07% below its 20 day moving average and -2.35% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $37.52 a share over the next twelve months. The current relative strength index (RSI) reading is 38.11.The technical indicator lead us to believe there will be no major movement any time soon, hold.
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops and commercializes medicines for various therapeutic areas, including inflammation/immunology, cardiovascular/metabolic, neuroscience/pain, and rare diseases. The VOC segment develops and commercializes vaccines, as well as products for oncology and consumer healthcare. It provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H brands; and respiratory and personal care products under the brand names of Robitussin, Advil Cold & Sinus, Advil Sinus Congestion Relief & Pain, Dimetapp, and ChapStick. The GEP segment offers products that have lost marketing exclusivity in various markets; and branded generics, generic sterile injectable products, biosimilars, infusion systems, and other products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has licensing agreements with Cellectis SA and AstraZeneca PLC; collaborative agreements with Eli Lilly & Company, OPKO Health, Inc., BioRap Technologies LTD., Merck KGaA, and Transgene S.A.; and a research and development agreement with the National Cancer Institute. The company has a partnership with The University of Pittsburgh; and a strategic collaboration agreement with IGNITE Immunotherapy Inc. It also has a collaboration with AbCellera Biologics Inc. to discover therapeutic antibodies against undisclosed membrane protein targets. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
QUALCOMM Incorporated (QCOM) shares were up in last trading by 0.35% to $54.24. It experienced higher than average volume on day. The stock decreased in value by almost -13.74% over the past week and fell -19.35% in the past month. It is currently trading -17.32% below its 50 day moving average and -9.81% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -23.67% decrease in value from its one year high of $71.62. The RSI indicator value of 25.25, lead us to believe that it may correct downwards in the near term.
QUALCOMM Incorporated develops, designs, manufactures, and markets digital communications products and services in China, South Korea, Taiwan, the United States, and internationally. The company operates through three segments: Qualcomm CDMA Technologies (QCT); Qualcomm Technology Licensing (QTL); and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on code division multiple access (CDMA), orthogonal frequency division multiple access (OFDMA), and other technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses or provides rights to use portions of its intellectual property portfolio, which include various patent rights useful in the manufacture and sale of certain wireless products comprising products implementing CDMA2000, WCDMA, CDMA TDD, and/or LTE standards, as well as their derivatives. The QSI segment invests in early-stage companies in various industries, including digital media, e-commerce, healthcare, and wearable devices for supporting the design and introduction of new products and services for voice and data communications. The company also develops and offers products for implementation of small cells; mobile health products and services; software products, and content and push-to-talk enablement services to wireless operators; and development, and other services and related products to the United States government agencies and their contractors. In addition, it licenses chipset technology and products for data centers. QUALCOMM Incorporated was founded in 1985 and is headquartered in San Diego, California.
Bristol-Myers Squibb Company (BMY) traded within a range of $47.12 to $48.62 after opening the day at $47.26. The company has seen its stock decrease in value by -17.77% so far this year. The stock was up close to 1.96% on active volume in last trading session and closed at $47.74 per share. After the recent gain, the stock is currently holding -37.26% below its 52 week high of $77.12 and 3.76% above its 12-month low of $46.01. The shares are down by over -2.51% in the last three months, and the RSI indicator value of 25.76 is bullish. They are not pointing to a rebound in the stock. We should get in as it looks to have found a bottom.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung and renal cell cancer, and melanoma; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for metastatic melanoma; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company has clinical trial collaborations with Calithera Biosciences, Inc. and Janssen Biotech, Inc.; and a research collaboration with GeneCentric Diagnostics, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.